In the clinical trial Sensor-Augmented Pump Therapy for A1C Reduction ( STAR 3 ) , 329 adults with type 1 diabetes were randomly allocated to either SAP or glargine-based multiple daily injection ( MDI ) therapy at 26 US sites ( n = 271 ) and 4 Canadian sites ( n = 58 ) .